Literature DB >> 8771063

Levodopa stability in solution: time course, environmental effects, and practical recommendations for clinical use.

E J Pappert1, C Buhrfiend, J W Lipton, P M Carvey, G T Stebbins, C G Goetz.   

Abstract

We defined the temporal stability characteristics of levodopa/carbidopa (LD/CD) solution, and determined the effects of temperature, ascorbate, and light on LD stability over 7 days. At room temperature and without ascorbate, LD levels significantly declined by 48 h. Ascorbate prolonged stability to 72 h. Refrigeration and freezing prevented a significant decline in LD levels for the full 7 days. Light or darkness had no effect on stability. LD/CD solution, if made daily, requires no special handling and longer stability is maintained with ascorbate, refrigeration, or freezing.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8771063     DOI： 10.1002/mds.870110106

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


  8 in total

Review 1.  Using liquid levodopa in the treatment of Parkinson's disease. A practical guide.

Authors:  M C Kurth
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

Review 2.  Determination of levodopa by chromatography-based methods in biological samples: a review.

Authors:  Ruiqi Jiang; Jiayu Yang; Shenghui Mei; Zhigang Zhao
Journal:  Anal Sci       Date:  2022-06-17       Impact factor: 1.967

3.  Development of Jelly Loaded with Nanogel Containing Natural L-Dopa from Mucuna pruriens Seed Extract for Neuroprotection in Parkinson's Disease.

Authors:  Chuda Chittasupho; Sarin Tadtong; Suwanna Vorarat; Witcha Imaram; Sirivan Athikomkulchai; Weerasak Samee; Vipaporn Sareedenchai; Thanu Thongnopkoon; Siriporn Okonogi; Narisa Kamkaen
Journal:  Pharmaceutics       Date:  2022-05-17       Impact factor: 6.525

Review 4.  Continuous drug delivery in Parkinson's disease.

Authors:  Marina Senek; Dag Nyholm
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

5.  Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study.

Authors:  R Katzenschlager; A Evans; A Manson; P N Patsalos; N Ratnaraj; H Watt; L Timmermann; R Van der Giessen; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-12       Impact factor: 10.154

6.  Can Patients with Parkinson's Disease Use Dry Powder Inhalers during Off Periods?

Authors:  M Luinstra; A W F Rutgers; H Dijkstra; F Grasmeijer; P Hagedoorn; J M J Vogelzang; H W Frijlink; A H de Boer
Journal:  PLoS One       Date:  2015-07-14       Impact factor: 3.240

7.  Ascorbic acid can alleviate the degradation of levodopa and carbidopa induced by magnesium oxide.

Authors:  Noriyuki Miyaue; Madoka Kubo; Masahiro Nagai
Journal:  Brain Behav       Date:  2022-06-17       Impact factor: 3.405

Review 8.  Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.

Authors:  Dag Nyholm
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 5.577
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.